Meeting
2022 ASCO Annual Meeting
Shedding of ctDNA, radiomics assessment of tumor disease volume (TDV), and concordance of mutations (mut) in synchronous liquid and tumor biopsies in metastatic breast cancer (MBC).
Authors
Andri Papakonstantinou
Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Group, Vall D´Hebron Institute of Oncology (VHIO), Barcelona, Spain
Andri Papakonstantinou , Alberto Gonzalez-Medina , Judit Matito , Marta Ligero , Fiorella Ruiz-Pace , Anna Suñol , Joaquin Rivero , Roberta Fasani , Mara Cruellas , Vicente Peg , Maria Borrell , Isabel Pimentel , Santiago Escriva De Romani Munoz , Judith Balmana Gelpi , Paolo Nuciforo , Rodrigo Dienstmann , Cristina Saura , Raquel Perez-Lopez , Mafalda Oliveira , Ana Vivancos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1086)
DOI
10.1200/JCO.2022.40.16_suppl.1086
Abstract #
1086
Poster Bd #
464
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).
First Author: Mafalda Oliveira
Poster
2023 ASCO Annual Meeting
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
First Author: Arielle J Medford
Poster
2020 ASCO Virtual Scientific Program
Patient-matched tissue and liquid biopsies identify shared and acquired genomic alterations in breast cancer.
First Author: Ethan Sokol